SBIR/STTR Research Award
A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis
Award amount
$224,347Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Angion Biomedica Corp.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- FCRJS1FGND63
- Solicitation number
- PA13-234
- Topic code
- NIAAA
Research abstract
DESCRIPTION (provided by applicant): Chronic Pancreatitis (CP) is characterized by continuous or recurrent inflammation of the pancreas that leads to permanent destruction of the pancreas resulting in exocrine and endocrine insufficiency. CP is a common disorder associated with significant morbidity and mortality with an incidence of 8.2 and a prevalence of 27.4 per 100 000 population. The etiology of CP is complex and about 70% of cases are due to excessive alcohol consumption. Alcoholic chronic pancreatitis is one of the more painful and serious consequences of alcohol, and the role of alcohol as a predisposing factor in severe pancreatitis is underappreciated. The most critical step for development of chronic pancreatitis is activation of pancreatic stellate cells (PSCs) and increased extracellular matrix (ECM) deposition that leads to fibrosis. Several growth factors, cytokines and alcohol can induce PSCs activation. Pancreatic fibrosis is a constant histopathological feature of chronic pancreatitis
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Targeted Therapeutics for Liver Disease
- ROCK selective inhibitor for Chronic Kidney Disease
- Steroid β hydroxylase inhibitor for Cushing s Syndrome
- Aldosterone Synthase Inhibitor for CKD
- SBIR Phase I: A Novel Extended Delivery Dual-action Platform for Peptide-based Anti-fibrotics
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
- DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)
- SBIR PHASE I - WEARABLE BIOSENSOR THAT QUANTIFIES BLOOD ALCOHOL CONCENTRATION IN REAL TIME
- THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.
- Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
Research funding history
75 SBIR/STTR records share this UEI (1999–2019). Reported award amounts total $60,879,018. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation